Jazz Pharmaceuticals posted strong Q1 2026 results with total revenues of $1.1 billion, a 19% increase year-over-year, driven by growth in key products like Xywav, Epidiolex, and Zepzelca. The FDA granted Priority Review for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, with a PDUFA date set for August 25, 2026, signaling potential new treatment options. The company reaffirmed its 2026 revenue and expense guidance and highlighted ongoing pipeline advancements and business development efforts aimed at long-term growth.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Atlas Energy Solutions (AESI) shares fell 25% due to removal from the Russell Growth Index and sector challenges, but the company secured a major CAT engine deal providing 1.6 GW of low-cost power. This deal supports strong free cash flow growth thro...
XRP's supply held on centralized exchanges has dropped to its lowest level in seven years, indicating reduced near-term sell pressure as holders move tokens to self-custody wallets. Despite this positive supply-side signal, XRP's price remains weak, ...
